Northwest BiotherapeuticsNWBO
13F holders, Q1 2024 (March 31)10holders
$0.52avg. 13F price*
At the end of Q1 2024, 10 institutions reported holding Northwest Biotherapeutics (NWBO) in their 13F filings. The largest holders were Moloney Securities Asset Management, LLC ($197K), Opus Capital Group, LLC ($31K) and Williams Jones Wealth Management, LLC. ($21K).
- Company
- Northwest Biotherapeutics
- Filed as
- NW Biotherapeutics (Q1 2024)
- CUSIP
- 66737P600
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $39K |
| Exits | 1 | $3K |
Ownership 10 holders
| Moloney Securities Asset Management, LLC | 0.03% | Add +6.0% | 379,460 | $197K |
| Opus Capital Group, LLC | 0.00% | No change | 60,150 | $31K |
| Williams Jones Wealth Management, LLC. | 0.00% | Reduce -9.1% | 40,000 | $21K |
| Maripau Wealth Management LLC | 0.02% | New | 39,493 | $20K |
| Ethos Financial Group, LLC | 0.00% | New | 23,700 | $12K |
| MAI Capital Management | 0.00% | No change | 20,000 | $10K |
| AlphaMark Advisors, LLC | 0.00% | New | 14,007 | $7K |
| Advisors Management Group Inc. | 0.00% | No change | 10,270 | $5K |
| Hantz Financial Services, Inc. | 0.00% | No change | 250 | $0 |
| Coston, McIsaac & Partners | 0.00% | No change | 1,000 | $0 |
"% of holder's portfolio" is NWBO's weight in each manager's 13F, not the share of Northwest Biotherapeutics the manager owns.